PTGS2 and neoplasm: Using this approach, we monitored the efficacy of chemoimmunotherapy with or without COX-2 inhibition in controlling tumor re-emergence at the primary site and the metastatic spread of 4T1 cells starting treatment post-tumor resection (Fig. 7a).